NucliThera is an R&D company developing targeted short-range radionuclides for treating hematological cancers like lymphoma and leukemia.
High-energy alpha- and beta-radiating nuclides are linked to targeting monoclonal antibodies or small molecules. They bind to cancer cells killing them with minimal damage to surrounding healthy tissue.
The NucliThera research team is led by Dr. Roy H Larsen and Professor Emeritus Øyvind S Bruland. They have developed the only alpha-emitting cancer pharmaceutical approved by FDA so far – Xofigo against bone metastases from prostate cancer. Xofigo was acquired by Bayer Healthcare for US$ 2.9 billion in 2014.
Company Details
- Employees
- 4
- Address
- Kjelsåsveien 168b, Oslo,0884,norway
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://nuclithera.com/
- Keywords
- in laboratory management.
- HQ
- Oslo
Nuclithera Questions
Nuclithera's website is http://nuclithera.com/
Nuclithera's LinkedIn profile is https://no.linkedin.com/company/nuclithera
Nuclithera has
4 employees.
View email and phone details for 4
employees at Nuclithera.
Nuclithera's industry is
Biotechnology Research
Nuclithera's top competitors are
Sharelab,
Medicare Llc,
Norsk Forening Farlig Avfall (Nffa),
Radiopharmaceutical Shippers & Carriers Committee,
Node Pharma,
Thor Medical Asa,
Artbio,
Zelluna,
Women In Life Science Norway (Wild Norway),
Xelle Ventures.
Nuclithera's categories are Biotechnology Research
